SOD1

SOD1 Molekülinformation

Englischer Name	Superoxide dismutase	Anzahl der inverkehr gebrachten Arzneimittel	3
Anzahl der klinischen Arzneimittel	13	Target-Alias	SOD1，Superoxide Dismutase 1，HSod1，Amyotrophic Lateral Sclerosis 1 (Adult)，Epididymis Secretory Protein Li 44，Superoxide Dismutase [Cu-Zn]，Cu/Zn Superoxide Dismutase，Indophenoloxidase A，SOD， Soluble，EC 1.15.1.1，HEL-S-44，IPOA，ALS1，SOD，ALS，Superoxide Dismutase，STAHP，EC:1.15.1.1，Superoxide Dismutase 1， Soluble，Superoxide Dismutase， Cystolic，Homodimer
Höchste Forschungs- und Entwicklungsphase	Approved

Englischer Name	Superoxide dismutase
Target-Alias	SOD1，Superoxide Dismutase 1，HSod1，Amyotrophic Lateral Sclerosis 1 (Adult)，Epididymis Secretory Protein Li 44，Superoxide Dismutase [Cu-Zn]，Cu/Zn Superoxide Dismutase，Indophenoloxidase A，SOD， Soluble，EC 1.15.1.1，HEL-S-44，IPOA，ALS1，SOD，ALS，Superoxide Dismutase，STAHP，EC:1.15.1.1，Superoxide Dismutase 1， Soluble，Superoxide Dismutase， Cystolic，Homodimer
Anzahl der inverkehr gebrachten Arzneimittel	3
Anzahl der klinischen Arzneimittel	13
Höchste Forschungs- und Entwicklungsphase	Approved

SOD1 Produktliste

Attribut
Protein (1)
Produktbibliothek
Online (1)
Spezies
Human (1)
Etikett
His Tag (1)
Marker
Unconjugated (1)

Produktnummer	Spezies	Expressionssystem	Produktbeschreibung	Proteinstruktur	Reinheit	Eigenschaften	Vorbestellen/Bestellen
SO1-H5148	Human	E. coli	Human SOD1 / Cu-Zn SOD Protein, His Tag, low Endotoxin (active enzyme)				In den Warenkorb legen

Gesamtmenge1

SOD1 Molekülhintergrund

Superoxide dismutase [Cu-Zn] (SOD1) is also known as superoxide dismutase 1 (hSod1), an enzyme that in humans is encoded by the SOD1 gene, located on chromosome 21. SOD1 can bind copper and zinc ions and is one of three superoxide dismutases responsible for destroying free superoxide radicals in the body. The encoded isozyme (SOD1) is a soluble cytoplasmic and mitochondrial intermembrane space protein, acting as a homodimer to convert naturally occurring, but harmful, superoxide radicals to molecular oxygen and hydrogen peroxide. Furthermore, the mutations of SOD1 gene can result in a neurodegenerative disorder affecting upper motor neurons in the brain and lower motor neurons in the brain stem and spinal cord.

SOD1 Molekülalias

SOD1,Superoxide dismutase 1,hSod1

Klinische Arzneimittelinformation

Englischer Name	Forschungscode	Forschungsphase	Firma	Indikationen	Klinische Studie
Otaplimastat	SP-8203 hydrochloride; SP8203 HCL; SP-8203	Phase 3 Clinical	Shin Poong Pharmaceutical Co Ltd	Ischemic Stroke	Details
Bis-choline tetrathiomolybdate	ATN-224; WTX-101; ALXN-1840	Phase 2 Clinical	Wilson Therapeutics	Hepatolenticular Degeneration; Melanoma; Multiple Myeloma; Prostatic Neoplasms	Details
Superoxide dismutase (Ube Industries)	r-hSOD; FKU-871	Phase 2 Clinical	Astellas Pharma Inc, Ube Industries Ltd	Diabetic Neuropathies; Myocardial Ischemia	Details
BMX-010	BMX-010; MnTE-2-PyP; MnTE-2-PyP5+	Phase 2 Clinical	Duke University	Acne Vulgaris; Dermatitis, Atopic; Psoriasis; Rosacea	Details
Tempol	MBM-02; OT-674; NSC-142784; MTS-02; MTS-10; MTS-01; APC-410; APC-400; REC-994; MBM-01; REC-0000994	Phase 2 Clinical	Mitos	Alopecia; Anus Neoplasms; Ataxia Telangiectasia; Cardiovascular Diseases; Coronavirus Disease 2019 (COVID-19); Drug-Related Side Effects and Adverse Reactions; Glioblastoma; Hemangioma, Cavernous, Central Nervous System; Mucositis; Ototoxicity; Prostatic Neoplasms	Details
Superoxide dismutase analogue (LTT Bio-Pharma)	LT-1001; LT-0011; PC-SOD NE; PC-SOD; LT-1002	Phase 2 Clinical	LTT Bio-Pharma Co Ltd	Colitis, Ulcerative; Idiopathic Pulmonary Fibrosis; Myocardial Infarction; Peripheral Nervous System Diseases; Respiratory Distress Syndrome, Adult; Stroke	Details
RAG-17	RAG-17; RD-12500	Phase 2 Clinical	Ractigen Therapeutics (Nantong) Co Ltd	Amyotrophic Lateral Sclerosis	Details
ALN-SOD	ALN-SOD	Phase 2 Clinical	Alnylam Pharmaceuticals Inc	Amyotrophic Lateral Sclerosis	Details
NI-005	AP-101 (AL-S Pharma); NI-005	Phase 2 Clinical	Al-S Pharma Ag	Amyotrophic Lateral Sclerosis	Details
APB-102	APB-102; AMT-162	Phase 2 Clinical	University Of Massachusetts Medical School	Amyotrophic Lateral Sclerosis	Details
NAS150	AEOL-10150; NAS150; NAS-150	Phase 1 Clinical	Aeolus Pharmaceuticals	Idiopathic Pulmonary Fibrosis; Lung Injury; Neoplasms; Supranuclear Palsy, Progressive	Details
INS-1202	INS1202; INS-1202	Phase 1 Clinical	Insmed	Amyotrophic Lateral Sclerosis	Details
[89Zr]Zr-DFO-AP-101		Phase 1 Clinical	Université De Sherbrooke	Amyotrophic Lateral Sclerosis; Tooth Diseases	Details

Inverkehr gebrachte Arzneimittelinformation

Englischer Name	Forschungscode	Forschungsphase	Firma	Frühestes Markenname	Frühestes Genehmigungsland	Früheste Indikation	Früheste Genehmigungsgesellschaft	Früheste Genehmigungsdatum	Indikationen	Klinische Studie
Orgotein		Approved	Gt Biopharma Inc	Ontosein	Spain	Rheumatic Diseases; Cystitis; Radiation Injuries	null	1996-01-01	Cystitis; Radiation Injuries; Rheumatic Diseases	Details
Cupric Sulfate/Manganese sulfate/Selenious acid/Zinc Sulfate		Approved	American Regent Inc	MULTRYS	United States	Dietary Supplement	American Regent Inc	2020-07-02	Dietary Supplement	Details
Tofersen	99mTc-MAG3-BIIB067; ISIS-333611; BIIB-067; SODr/h333611; ISIS-SOD1Rx; IONIS SOD1Rx	Approved	Ionis Pharmaceuticals Inc, Ludwig Institute For Cancer Research	QALSODY, Qalsody, 凯盛迪	United States	Amyotrophic Lateral Sclerosis	Biogen Ma Inc, Biogen Inc	2023-04-25	Amyotrophic Lateral Sclerosis; Familial Amyotrophic Lateral Sclerosis	Details